Drug intelligence / Profile preview

Carnaculin + V-Omin

Development stage
Unknown
Lead developer
Sanwa
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Carnaculin + V-Omin is a combination therapy developed by AJU Pharm Co., Ltd. for the treatment of non-proliferative diabetic retinopathy (NPDR). Carnaculin contains kallidinogenase (pancreatic kininogenase), a proteolytic enzyme that cleaves kininogen to produce kinins, which promote vasodilation and improve retinal microcirculation. V-Omin is a vitamin B complex featuring benfotiamine, a lipid-soluble thiamine derivative that activates the enzyme transketolase. This activation helps divert excess glucose metabolites into the pentose phosphate pathway, thereby inhibiting the formation of advanced glycation end-products (AGEs) and reducing oxidative stress associated with diabetic microvascular damage. The combination is evaluated for its ability to reduce hard exudates and stabilize retinal health in NPDR patients.

Other names
kallidinogenase + benfotiamine
02

Targets

KNG1 (High-molecular-weight kininogen)TKT (Transketolase)

Beyond the preview

Go deeper on Carnaculin + V-Omin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carnaculin + V-Omin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call